189 related articles for article (PubMed ID: 24719188)
1. Periostin is a new potential prognostic biomarker for glioma.
Tian B; Zhang Y; Zhang J
Tumour Biol; 2014 Jun; 35(6):5877-83. PubMed ID: 24719188
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic reg IV is a novel prognostic marker for glioma patient survival.
Wang Q; Deng J; Yuan J; Wang L; Zhao Z; He S; Zhang Y; Tu Y
Diagn Pathol; 2012 Jun; 7():69. PubMed ID: 22713481
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
4. Circulating CD133(+)/ESA(+) cells in colorectal cancer patients.
Tseng JY; Yang CY; Yang SH; Lin JK; Lin CH; Jiang JK
J Surg Res; 2015 Dec; 199(2):362-70. PubMed ID: 26119272
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of periostin in the liver metastasis of colorectal cancer.
Wu G; Wang X; Zhang X
Cancer Biother Radiopharm; 2013 May; 28(4):298-302. PubMed ID: 23347152
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
[TBL] [Abstract][Full Text] [Related]
7. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
[TBL] [Abstract][Full Text] [Related]
8. Stem cell marker CD133 affects clinical outcome in glioma patients.
Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
[TBL] [Abstract][Full Text] [Related]
9. Periostin is a novel therapeutic target that predicts and regulates glioma malignancy.
Mikheev AM; Mikheeva SA; Trister AD; Tokita MJ; Emerson SN; Parada CA; Born DE; Carnemolla B; Frankel S; Kim DH; Oxford RG; Kosai Y; Tozer-Fink KR; Manning TC; Silber JR; Rostomily RC
Neuro Oncol; 2015 Mar; 17(3):372-82. PubMed ID: 25140038
[TBL] [Abstract][Full Text] [Related]
10. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
Jiang S; Pei L; Yang ZL; Liu G
Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of midkine and pleiotrophin predicts poor survival in human glioma.
Ma J; Lang B; Wang X; Wang L; Dong Y; Hu H
J Clin Neurosci; 2014 Nov; 21(11):1885-90. PubMed ID: 25001988
[TBL] [Abstract][Full Text] [Related]
13. BMP4, a new prognostic factor for glioma.
Wu Q; Yao J
World J Surg Oncol; 2013 Oct; 11():264. PubMed ID: 24099560
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognostic value of JAM-A in gliomas.
Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
[TBL] [Abstract][Full Text] [Related]
15. The overexpression of epithelial cell adhesion molecule (EpCAM) in glioma.
Chen X; Ma WY; Xu SC; Liang Y; Fu YB; Pang B; Xin T; Fan HT; Zhang R; Luo JG; Kang WQ; Wang M; Pang Q
J Neurooncol; 2014 Aug; 119(1):39-47. PubMed ID: 24906438
[TBL] [Abstract][Full Text] [Related]
16. Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma.
Yu JW; Zhang P; Wu JG; Wu SH; Li XQ; Wang ST; Lu RQ; Ni XC; Jiang BJ
J Exp Clin Cancer Res; 2010 Nov; 29(1):141. PubMed ID: 21054902
[TBL] [Abstract][Full Text] [Related]
17. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic expression of BAP1 as an independent prognostic biomarker for patients with gliomas.
Zhang XK; Xi SY; Sai K; Chen HD; Zhong ZH; Wu QL; Zeng J
Int J Clin Exp Pathol; 2015; 8(5):5035-43. PubMed ID: 26191197
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma.
Wang L; He S; Tu Y; Ji P; Zong J; Zhang J; Feng F; Zhao J; Gao G; Zhang Y
J Clin Neurosci; 2013 Jul; 20(7):958-63. PubMed ID: 23707602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
